Crizotinib neuroblastoma study 'very promising'
A new way of using a drug called crizotinib in combination with a second class of drugs to treat neuroblastoma has shown “very promising” results, scientists said.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
- Customised email alerts straight to your inbox (30+ alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units